Literature DB >> 23588599

Cardiac syncope due to pain: report of a case responsive to duloxetine treatment.

C Kaplan1, S A Kocaman, M E Durakoğlugil, E Kaya, M G Senol.   

Abstract

Neurocardiogenic syncope comprises situations triggered by neurological reflexes resulting in abnormal responses of the neurocardiovascular system that cause loss of consciousness. A vast number of clinical conditions may cause this disorder including pain, defecation, micturition, swallowing, cough, sudden fear or excitement, exercise, and long-time standing. Treatment options for syncope prevention are not satisfactory. Several agents were used for pharmacological treatment without success. Selective inhibitors of neuronal norepinephrine transporter (NET) like duloxetine may play a role in neurally mediated syncope by increasing synaptic norepinephrine levels. Therefore, we report the effect of duloxetine in a patient with pain-induced syncope resistant to standard regimens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588599     DOI: 10.1007/s00059-012-3734-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  7 in total

Review 1.  Duloxetine in diabetic neuropathy.

Authors:  Timothy R Smith
Journal:  Expert Opin Pharmacother       Date:  2006-02       Impact factor: 3.889

2.  Glossopharyngeal neuralgia with cardiac syncope: an idiopathic case treated with carbamazepine and duloxetine.

Authors:  E Giza; P Kyriakou; C Liasides; A Dimakopoulou
Journal:  Eur J Neurol       Date:  2008-03-18       Impact factor: 6.089

3.  Guidelines for the diagnosis and management of syncope (version 2009).

Authors:  Angel Moya; Richard Sutton; Fabrizio Ammirati; Jean-Jacques Blanc; Michele Brignole; Johannes B Dahm; Jean-Claude Deharo; Jacek Gajek; Knut Gjesdal; Andrew Krahn; Martial Massin; Mauro Pepi; Thomas Pezawas; Ricardo Ruiz Granell; Francois Sarasin; Andrea Ungar; J Gert van Dijk; Edmond P Walma; Wouter Wieling
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

4.  Norepinephrine transporter inhibition prevents tilt-induced pre-syncope.

Authors:  Christoph Schroeder; Andreas L Birkenfeld; Antje F Mayer; Jens Tank; Andre Diedrich; Friedrich C Luft; Jens Jordan
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

5.  Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans.

Authors:  M D Esler; G Wallin; P K Dorward; G Eisenhofer; R Westerman; I Meredith; G Lambert; H S Cox; G Jennings
Journal:  Am J Physiol       Date:  1991-04

Review 6.  Evidence-based treatment for vasovagal syncope.

Authors:  Vikas Kuriachan; Robert S Sheldon; Michael Platonov
Journal:  Heart Rhythm       Date:  2008-08-28       Impact factor: 6.343

7.  Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation.

Authors:  Sebastian Strempel; Christoph Schroeder; Ruth Hemmersbach; Andrea Boese; Jens Tank; André Diedrich; Martina Heer; Friedrich C Luft; Jens Jordan
Journal:  J Appl Physiol (1985)       Date:  2008-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.